Statement from Professor Ewan McKendrick, Registrar of Oxford University, regarding BBC’s File on 4 programme (6 June 2017) examining the role of animal experiments in the development of a new human vaccine for tuberculosis.
Whether a painful strep throat turns into a fatal case of heart disease depends not just on prompt antibiotic treatment but also on the patient’s genetic makeup, according to a new study led by Oxford University scientists. The discovery could help the long fight to find a vaccine against Group A streptococcus bacteria, which cause strep throat, scarlet fever and rheumatic heart disease. The Oxford study, published in Nature Communications this month, was done in Fiji, New Caledonia and other South Pacific islands “because it’s one of the top reasons young people die there,” said Dr. Tom Parks, lead author and part of Prof Adrian Hill's genetics group which studies genetic susceptibility to infectious diseases.
A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. The partnership, which is led by Prof Tomáš Hanke at the Jenner Institute, will evaluate a new vaccine that triggers the body to produce T-cells, at four sites in Kenya, Uganda and Zambia. Professor Tomáš Hanke said: 'There is enormous variation between HIV strains worldwide, which as well as making treatment difficult, has also been an obstacle to developing a vaccine. By using small parts common to most HIV strains, if successful, the vaccine could be used around the world, especially in Africa which is most affected by the HIV pandemic.'
p53 is one of the most damaged genes in cancer. Because p53 stays inside the cells, it is not straightforward to identify and kill the cells with damaged p53. Jenner Institute researcher, Dr Nicola Ternette has developed an antibody that recognises a p53 fragment presented on cancer cell surface and shows in a recent publication that this antibody is a promising new drug for cancer immunotherapy.
An Oxford University spinout company is developing a molecular superglue for the rapid development of vaccines targeting a range of diseases. SpyBiotech, co-founded by Jenner researchers Sumi Biswas, Jing Jin and Simon Draper aims to facilitate the rapid development of robust and novel vaccines.
The tenth anniversary of the European Research Council (ERC) has been marked by a series of events and a video featuring some of Oxford's recipients of ERC funding. In a video to mark the anniversary, a number of Oxford University academics have explained how ERC funding has been vital to their research, including Adrian Hill, Director of the Jenner Institute.
A new call for Medical Research Council (MRC) Confidence in Concept funding has just been launched as part of the Tropical Infectious Disease Consortium (Jenner Institute, London School of Hygiene & Tropical Medicine, Liverpool School of Tropical Medicine, and Public Health England). The MRC are ...
A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. Led by Professor Tomáš Hanke at the Jenner Institute, the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the body to produce specialised immune cells called T-cells, which will be trialled at four sites in Kenya, Uganda and Zambia.
University of Oxford/University of Cape Town PhD Exchange Programme: Applications are open for the Newton/RCUK PhD partnership scheme for PhD students within medical sciences. There is an opportunity for 8 University of Oxford DPhil students to visit the University of Cape Town on a 4 month exchange visit, with an equivalent opportunity for University of Cape Town PhD students to visit the University of Oxford. The scheme covers the costs of the exchange visits, a stipend, a contribution to research and bench fees or equivalent and additional partnering activities.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.